Analysis of previously published RNA sequencing data from a series of osimertinib tolerant EGFR mutated lung cancer cell lines (Gogleva et al., 2022) revealed higher expression levels of FYN and KDM4A in the drug persisters, but not SRC (Figure 5B). The gene discussed is EGFR; the disease is lung carcinoma.